Although tranilast has a much lower affinity for the AHR than 3-MC, it can induce comparable expression of CYP1A1 in breast cancer cells when added to cultures at pharmacological concentrations (≥100 μM). This evidence concerns the gene CYP1A1 and breast carcinoma.